3-氯-6-(1H-吡唑-1-基)哒嗪 | 29334-66-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-氯-6-(1H-吡唑-1-基)哒嗪
• 中文别名: 3-氯-6-(1H-吡唑)哒嗪
• 英文名称: 3-chloro-6-(1H-pyrazol-1-yl)pyridazine
• 英文别名: 3-chloro-6-pyrazol-1-ylpyridazine
• CAS: 29334-66-5
• 化学式: C₇H₅ClN₄
• mdl: MFCD09261072
• 分子量: 180.596
• InChiKey: KAGZGWUUTROZIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Chloro-6-(1H-pyrazol-1-yl)pyridazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-6-(1H-pyrazol-1-yl)pyridazine
CAS number: 29334-66-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5ClN4
Molecular weight: 180.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯-6-(1H-吡唑-1-基)哒嗪 在 sodium hypochlorite 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以74%的产率得到3-chloro-6-(4-chloro-1H-pyrazol-1-yl)pyridazine
  参考文献：
  名称：

  Synthesis, Antibacterial and Antioxidant Properties of Pyrazolylpyridazines

  摘要：

  A number of 6-chloro-3-(pyrazol-1'-yl) pyridazines were prepared from 3,6-dichloropyridazine via either reaction with hydrazine followed by reaction with appropriate reagents to develop the pyrazole or through a nucleophilic reaction with a pyrazole. Some electrophilic reactions gave the corresponding 4'-substituted pyrazolylpyridazines. All the compounds were tested for their in vitro antibacterial as well as their antioxidant properties.

  DOI：

  10.14233/ajchem.2013.14590
• 作为产物：
  描述：

  吡唑 、 3,6-二氯哒嗪 在 1.) K 作用下， 以 四氢呋喃 为溶剂， 以74%的产率得到3-氯-6-(1H-吡唑-1-基)哒嗪
  参考文献：
  名称：

  Blake, Alexander J.; Hubberstey, Peter; Li, Wan-Sheung, Journal of the Chemical Society, Dalton Transactions, 1998, # 4, p. 647 - 655

  摘要：

  DOI：

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021123291A1

  公开（公告）日：2021-06-24

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性核瘫痪；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病、帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍）、带有Lewy小体的痴呆、多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。
• [EN] OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DÉRIVÉS D'OXADIAZOLYLTHIOPHÈNE À UTILISER EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：KARUS THERAPEUTICS LTD

  公开号：WO2019166824A1

  公开（公告）日：2019-09-06

  A compound of Formula I : (I) or a pharmaceutically acceptable salt thereof, wherein: each R' is QR1; each Q is independently selected from a bond, -C1-C10 alkylene, -C2-C10 alkenylene, -C(O)-, -C(O)O-, -C(O)N(R1)-, -C(O)N(R1)SO2- -N(R1)C(O)-, - N(R1)-, -N(SO2(R1)), -N(R1)SO2- -C(O)NR4R5-, -N(R4R5)C(O)-, -N(R4R5)- - S-, -SO-, -SO2-, -S(O)O-, -SO2N(R1)- and -O-; each R1 is independently selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 haloalkyl, C1-C10 heteroalkyl, aryl, heteroaryl, C3-C10 cycloalkyl, -(C1-C10 alkylene)-C3-C10 cycloalkyl, halogen, cyano, C1-C10 alkylene- aryl, C1-C10 alkylene heteroaryl, C1-C10 heterocycloalkyl and -(C1-C10 alkylene)- C1-C10 heterocycloalkyl. The compounds are inhibitors of HDAC and therefore have potential utility in the therapy of a number of conditions including cancer and inflammation.

  一种Formula I的化合物：(I)或其药学上可接受的盐，其中：每个R'是QR1；每个Q独立地选自键，-C1-C10烷基，-C2-C10烯基，-C(O)-，-C(O)O-，-C(O)N(R1)-，-C(O)N(R1)SO2-，-N(R1)C(O)-，-N(R1)-，-N(SO2(R1))，-N(R1)SO2-，-C(O)NR4R5-，-N(R4R5)C(O)-，-N(R4R5)-，-S-，-SO-，-SO2-，-S(O)O-，-SO2N(R1)-和-O-；每个R1独立地选自H，C1-C10烷基，C2-C10烯基，C2-C10炔基，C1-C10卤代烷基，C1-C10杂原子烷基，芳基，杂芳基，C3-C10环烷基，-(C1-C10烷基)-C3-C10环烷基，卤素，氰基，C1-C10烷基-芳基，C1-C10烷基-杂原子芳基，C1-C10杂环烷基和-(C1-C10烷基)-C1-C10杂环烷基。这些化合物是HDAC的抑制剂，因此在治疗包括癌症和炎症在内的多种疾病中具有潜在用途。
• [EN] PYRROLIDINE AND BICYCLOHETEROARYL CONTAINING OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA CONTENANT DE LA PYRROLIDINE ET DE LA BICYCLOHÉTÉROARYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021094312A1

  公开（公告）日：2021-05-20

  The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GIcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病，如tau病变，特别是阿尔茨海默病或进行性上行性麻痹；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病，由帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍），具有Lewy小体的痴呆，多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。
• A new method for the synthesis and herbicidal activity of 3-phenoxy-6-(<i>1H-</i>(substituted)pyrazol-1-yl) pyridazines
  作者：Fang-Zhong Hu、Gui-Feng Zhang、Bin Liu、Xiao-Mao Zou、You-Quan Zhu、Hua-Zheng Yang

  DOI：10.1002/jhet.120

  日期：2009.7

  3-chloro-6-hydrazinyl pyridazine with 3-dimethylamino-acrylaldehyde or ethyl 2-((dimethylamino) methylene)-3-oxobutanoate in n-butanol under reflux, respectively, and side products or were also generated. All of the title compounds were confirmed by 1H NMR, infrared spectometry (IR) and elemental analyses. Preliminary bioassay indicated that some of the title compounds showed high inhibitory activity against Brassica

  由各种酚的缩合反应合成了一系列3-取代的苯氧基-6-（（取代的）1H-吡唑-1-基）哒嗪。3-氯-6-（1H-吡唑-1-基）哒嗪 或3-氯-6-（5'-甲基-4-乙氧基羰基-1H-吡唑-1-基）哒嗪 在 N，N-二甲基甲酰胺（DMF）在120°C，以K 2 CO 3为酸受体。中间体 或者 从环化获得3-氯-6-肼基哒嗪 和 3-二甲基氨基丙烯醛或乙基-2 - （（二甲基氨基）亚甲基）-3-氧代丁酸在正丁醇及回流副产物 或者 也产生了。所有标题化合物均通过1 H NMR，红外光谱（IR）和元素分析确认。生物活性测试表明，部分标题化合物显示高的抑制活性对油菜L.（白菜型油菜）和中度抑制活性对稗草。例如，化合物的抑制百分比 和 10μg/ mL时对菜子双歧杆菌的抗药性均为94％。J.杂环化​​学，（2009）。
• Ruthenium half-sandwich complexes with tautomerized pyrazolyl-pyridazine ligands: Synthesis, spectroscopic and molecular structural studies
  作者：Gajendra Gupta、Kota Thirumala Prasad、Babulal Das、Glenn P.A. Yap、Kollipara Mohan Rao

  DOI：10.1016/j.jorganchem.2009.03.043

  日期：2009.7

  pyrazolyl-pyridazine ligands, viz., (i) products of substitution on one side of the pyridazine as 3-chloro-6-(pyrazolyl)pyridazine (Cl–L1), 3-chloro-6-(3,5-dimethylpyrazolyl)pyridazine (Cl–L2) and 3-chloro-6-(3-methylpyrazolyl)pyridazine (Cl–L3), and (ii) products of substitution on both sides such as 3,6-bis(pyrazolyl)pyridazine (L1), 3,6-bis(3,5-dimethylpyrazolyl)pyridazine (L2) and tautomers of 3,6-bis(

  1,4-二氯哒嗪与吡唑，3,5-二甲基吡唑和3-甲基吡唑的缩合产生了两种类型的吡唑基-哒嗪配体，即，（i）哒嗪一侧的取代产物为3-氯-6- （吡唑基）哒嗪（Cl–L1）， 3-氯-6-（3,5-二甲基吡唑基）哒嗪（Cl–L2）和3-氯-6-（3-甲基吡唑基）哒嗪（Cl–L3）和（ ii）两侧的取代产物，例如3,6-双（吡唑基）哒嗪（L1），3,6-双（3,5-二甲基吡唑基）哒嗪（L2）和3,6-双（3-t互变异构体）甲基吡唑基）哒嗪（L3）。的η反应6 -areneruthenium络合物的甲醇溶液与上面提到的吡唑基-哒嗪配位体形成的类型[单核络合物（η 6-arene）的Ru（CL-L）（CL）] +和[（η 6 -arene）的Ru（L）（CL）] + ; （芳烃=苯和对甲基苯甲基； Cl–L = Cl–L1，Cl–L2，Cl–L3； L = L1，L2，L3）。所有这些配合物的特征在